New Republic Capital LLC cut its stake in Danaher Co. (NYSE:DHR – Free Report) by 6.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 899 shares of the conglomerate’s stock after selling 58 shares during the period. New Republic Capital LLC’s holdings in Danaher were worth $206,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the company. FMR LLC lifted its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. International Assets Investment Management LLC boosted its position in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. grew its stake in shares of Danaher by 30.4% during the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares during the period. Finally, Union Bancaire Privee UBP SA bought a new stake in Danaher in the fourth quarter valued at about $74,551,000. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Activity at Danaher
In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.10% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
View Our Latest Analysis on Danaher
Danaher Stock Down 1.6 %
DHR opened at $203.42 on Tuesday. The stock’s fifty day simple moving average is $232.72 and its 200 day simple moving average is $251.61. Danaher Co. has a 1-year low of $203.00 and a 1-year high of $281.70. The stock has a market cap of $146.92 billion, a PE ratio of 38.53, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm earned $2.09 EPS. As a group, research analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.
Danaher Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.53%. Danaher’s dividend payout ratio (DPR) is currently 20.45%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Differences Between Momentum Investing and Long Term Investing
- Fintech vs. Traditional Finance: Showdown of Nu, SoFi, and Chubb
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Onsemi Stock: Signs Point to a Powerful Rebound
- What is Put Option Volume?
- Monday.com Stock Could Soar to New Highs—Here’s How
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.